Primary Peritoneal
| Treatment Stage | Short Name | Protocol Title | ClinicalTrials.Gov Link | Penn Research Coordinator | Am I Eligible? |
|---|---|---|---|---|---|
| Stage II-IV Newly Diagnosed | GY019 | A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum | Eligibility Criteria | ||
| Any | Penn Legacy Tissue Program | Participation in the Ovarian Cancer Research Center Rapid Autopsy Program | N/A | Dalia Omran | Eligibility Criteria |
| Recurrent | CAPRI | CAPRI: Combination ATR and PARP Inhibitor (CAPRI) Trial with AZD6738 and Olaparib in Recurrent Ovarian Cancer | NCT03462342 | Shavon Rochester | Eligibility Criteria |
| Recurrent | MYTHIC | Phase 1 Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-6306 in Patients with Advanced Solid Tumors (MYTHIC Study) | NCT04855656 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | MAGNETIC | Phase 1 Study of the PKMYT1 Inhibitor RP-6306 in Combination with Gemcitabine for the Treatment of Advanced Solid Tumors (MAGNETIC Study) | NCT05147272 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | STRO+bev |
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor alpha (FolRα) Antibody DrugConjugate (ADC), in Combination with Bevacizumab in Patients with Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) |
NCT05200364 | Destany Fields |
Enrollment on Hold |
| Recurrent | FAETH | A Phase 1b Study of Serabelisib in Combination with an Insulin Suppressing Diet (Study ISD) in Subjects with Advanced Solid Tumors with PIK3CA Mutations with or without PTEN loss | NCT05300048 | Katie Elkins |
Enrollment on Hold |
| Recurrent | ATRIN | A Phase 1/2a, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral ATRN-119 in Patients with Advanced Solid Tumors | NCT04905914 | Andrea Standish, RN | Eligibility Criteria |
| Recurrent | Xencor | A Phase 2 Study of XmAb®20717 in Patients With Selected Gynecological Malignancies and High-Risk Metastatic Castration-Resistant Prostate Cancer | NCT05032040 | Isabel Forbes | Eligibility Criteria |
| Recurrent | GOG 3066 | A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT04814108 | Kristina Powell | Eligibility Criteria |
| Recurrent | GOG 3063 | A Phase 3, Multicenter, Open-Label, Randomized Study of Nemvaleukin Alfa in Combination With Pembrolizumab Versus Investigator’s Choice Chemotherapy in Patients With Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARTISTRY-7) | NCT05092360 | Shavon Rochester | Eligibility Criteria |
| Recurrent | STAR-101 | A Phase 1 Study of SynKIR-110, Autologous T cells Transduced with Mesothelin KIR-CAR, in Subjects with Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, or Mesothelioma | NCT05568680 | Katie Elkins | Eligibility Criteria |
| Recurrent | NP-G2-044-P2-01 | NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | NCT05023486 | Shavon Rochester | Eligibility Criteria |